Using macrophage activation to augment immunotherapy of established tumours

Neutrophil Influx and Chemokine Production during the Early Phases of the Antitumor Response to the Vascular Disrupting Agent DMXAA (ASA404)

(2015) Liang-Chuan S. Wang et al.   NEOPLASIA

Plasticity of Macrophage Function during Tumor Progression: Regulation by Distinct Molecular Mechanisms

(2014) S. K. Biswas et al.   JOURNAL OF IMMUNOLOGY

Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA

(2012) K Henare et al.   BRITISH JOURNAL OF CANCER

5,6-Dimethylxanthenone-4-acetic Acid (DMXAA) Activates Stimulator of Interferon Gene (STING)-dependent Innate Immune Pathways and Is Regulated by Mitochondrial Membrane Potential

(2012) Daniel Prantner et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Immunotherapy earns its spot in the ranks of cancer therapy

(2012) Drew Pardoll et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Activation of mitogen-activated protein kinases by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) plays an important role in macrophage stimulation

(2011) Jing Sun et al.   BIOCHEMICAL PHARMACOLOGY

Cancer-promoting tumor-associated macrophages: New vistas and open questions

(2011) Alberto Mantovani et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer

(2011) Primo N. Lara et al.   JOURNAL OF CLINICAL ONCOLOGY

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Temporal aspects of the action of ASA404 (vadimezan; DMXAA)

(2010) Bruce C Baguley et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Control of Cervicovaginal HPV-16 E7-Expressing Tumors by the Combination of Therapeutic HPV Vaccination and Vascular Disrupting Agents

(2010) Qi Zeng et al.   HUMAN GENE THERAPY

Activation of the Nucleotide Oligomerization Domain Signaling Pathway by the Non-bacterially Derived Xanthone Drug 5′6-Dimethylxanthenone-4-acetic Acid (Vadimezan)

(2010) Guanjun Cheng et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A Phase I Trial of Repeated Intrapleural Adenoviral-mediated Interferon-β Gene Transfer for Mesothelioma and Metastatic Pleural Effusions

(2010) Daniel H Sterman et al.   MOLECULAR THERAPY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

CCL2 Blockade Augments Cancer Immunotherapy

(2009) Z. G. Fridlender et al.   CANCER RESEARCH

Peptide inhibitors of transforming growth factor-β enhance the efficacy of antitumor immunotherapy

(2009) Diana Llopiz et al.   INTERNATIONAL JOURNAL OF CANCER

CCL2 and Interleukin-6 Promote Survival of Human CD11b+Peripheral Blood Mononuclear Cells and Induce M2-type Macrophage Polarization

(2009) Hernan Roca et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Systemic Blockade of Transforming Growth Factor-  Signaling Augments the Efficacy of Immunogene Therapy

(2008) S. Kim et al.   CANCER RESEARCH

Transforming Growth Factor-  Receptor Blockade Augments the Effectiveness of Adoptive T-Cell Therapy of Established Solid Cancers

(2008) A. Wallace et al.   CLINICAL CANCER RESEARCH

Clinical investigations of Toll-like receptor agonists

(2008) Thomas Meyer et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Cancer Immunology

(2008) Olivera J. Finn   NEW ENGLAND JOURNAL OF MEDICINE

Macrophage polarization in tumour progression

(2008) Antonio Sica et al.   SEMINARS IN CANCER BIOLOGY